Is OKYO or PCVX more undervalued in 2026?

CirclFi compares OKYO Pharma Limited (OKYO) and Vaxcyte, Inc. (PCVX) using 13 institutional-grade valuation models. OKYO has a Quality of Company score of 1.7/10 while PCVX scores 5.1/10.

Which is a better buy — OKYO or PCVX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OKYO and PCVX valuations compare?

OKYO at $1.72 and PCVX at $51.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OKYO vs PCVX Valuation Comparison 2026 — Intrinsic Value Analysis

OKYO

Biological Products, (No Diagnostic Substances)

OKYO Pharma Limited

Quality

1.7

out of 10

Value Trap

—

Price

$1.72

Last close

Models

8/13

Active

PCVX

Biological Products, (No Diagnostic Substances)

Vaxcyte, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$51.40

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	OKYO Fair Value	OKYO Upside	PCVX Fair Value	PCVX Upside
Bayesian DCF	Intrinsic	$0.43	-75.1%	$14.79	-71.2%
Earnings Power Value	Intrinsic	—	—	$27.17	-54.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$1.04	-39.6%	$45.95	-10.6%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OKYO vs PCVX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OKYO vs PCVX — Which Stock Is More Undervalued?

PCVX scores higher with a 5.1/10 quality rating vs OKYO's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing OKYO Pharma Limited (OKYO) and Vaxcyte, Inc. (PCVX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OKYO currently trades at $1.72 with a QOC of 1.7/10, while PCVX trades at $51.40 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).